[Alpha Biz= Reporter Kim Jisun] Mezzion Pharma announced on the 16th that it would acquire an additional 158 shares of its U.S. subsidiary, Mezzion Pharmaceuticals, for approximately 163.5 billion KRW. Mezzion Pharmaceuticals, a subsidiary of Mezzion, was established in the U.S. for the purpose of developing and selling new drugs.
Even after the acquisition, Mezzion's ownership stake remains 100%. The acquisition method involves converting a loan receivable into capital, and the purpose of the acquisition is to improve financial stability.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
